Dr. Swayampakula Ramakanth is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Ramakanth’s research covers companies operating in oncology, wound health, medical devices, spine health and animal health. Dr. Ramakanth possesses over ten years of experience as a Life Sciences Equity Analyst as well as seven years of biotechnology industry experience. Prior to joining H.C. Wainwright, Dr. Ramakanth worked as a Junior Analyst at both Jefferies and Merrill Lynch covering large cap pharmaceuticals.
SmarterAnalyst, 1 May 2020
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 36.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, IntelGenx Technologies, and Corvus Pharmaceuticals.
TheFly, 10 January 2020
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $1.20 price target on Ekso Bionics, saying the pre-announced “record” fourth quarter “bodes well” for continued growth in 2020.
StreetInsider.com, 28 October 2019
H.C. Wainwright analyst Swayampakula Ramakanth initiates coverage on Ekso Bionics (NASDAQ: EKSO) with a Buy rating and a price target of $1.20.
Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.